OHSU Knight Cancer Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Portland Oregon United States (1887)

Organization Overview

First Clinical Trial
2014
NCT02070705
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

OHSU Knight Cancer Institute

Active Ingredients

Drugs in Phase 4 Trials (3)

Fluciclovine (Axumin) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

piflufolastat (PYLARIFY) (1 trial)

Drugs in Phase 2 Trials (55)

abiraterone (zytiga) (2 trials)

alectinib (alecensa) (1 trial)

alpelisib (Piqray) (1 trial)

amiodarone (cordarone) (1 trial)

anastrozole (arimidex) (1 trial)

apalutamide (erleada) (1 trial)

aprepitant (Emend) (1 trial)

atezolizumab (Tecentriq) (2 trials)

atorvastatin (lipitor) (1 trial)

bevacizumab (avastin) (2 trials)

cabozantinib (cometriq) (2 trials)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (2 trials)

carfilzomib (kyprolis) (1 trial)

cobimetinib (cotellic) (3 trials)

dexamethasone (1 trial)

durvalumab (imfinzi) (2 trials)

entrectinib (Rozlytrek) (2 trials)

eribulin (halaven) (2 trials)

ferumoxytol (feraheme) (6 trials)

Filgrastim (neupogen) (1 trial)

floxuridine (fudr) (1 trial)

fluoromisonidazole (1 trial)

fluorouracil (efudex) (3 trials)

fulvestrant (faslodex) (1 trial)

heparin (liquaemin) (1 trial)

hyaluronidase (human recombinant) (Hylenex) (1 trial)

irinotecan (Camptosar) (3 trials)

Isatuximab (Sarclisa) (1 trial)

jnj-40346527 (1 trial)

letrozole (femara) (1 trial)

leucovorin (3 trials)

lopinavir (Kaletra) (1 trial)

losartan (cozaar) (1 trial)

lutetium dotatate lu-177 (Lutathera) (1 trial)

motexafin gadolinium (1 trial)

niraparib (zejula) (2 trials)

olanzapine (zyprexa) (1 trial)

olaparib (lynparza) (5 trials)

onabotulinumtoxinA (Botox) (1 trial)

ondansetron (zofran) (1 trial)

oxaliplatin (eloxatin) (3 trials)

paclitaxel (taxol) (1 trial)

palbociclib (ibrance) (2 trials)

pembrolizumab (keytruda) (3 trials)

pertuzumab (perjeta) (2 trials)

pomalidomide (pomalyst) (1 trial)

prednisone (meticorten) (2 trials)

ritonavir (Norvir) (1 trial)

trastuzumab (herceptin) (1 trial)

trastuzumab emtansine (kadcyla) (1 trial)

vemurafenib (zelboraf) (2 trials)

vinorelbine (navelbine) (1 trial)

vismodegib (erivedge) (1 trial)

xisomab 3g3 (1 trial)

Drugs in Phase 1 Trials (42)

abemaciclib (verzenio) (1 trial)

acalabrutinib (calquence) (1 trial)

afatinib (gilotrif) (1 trial)

bortezomib (velcade) (1 trial)

cabazitaxel (jevtana kit) (1 trial)

calaspargase pegol (Asparlas) (1 trial)

cedazuridine (Inqovi) (1 trial)

celecoxib (celebrex) (1 trial)

cytarabine (cytosar-u) (2 trials)

dasatinib (sprycel) (2 trials)

daunorubicin (cerubidine) (2 trials)

decitabine (dacogen) (1 trial)

enzalutamide (xtandi) (1 trial)

erlotinib (tarceva) (1 trial)

everolimus (zortress) (1 trial)

fluorothymidine (1 trial)

gemtuzumab ozogamicin (mylotarg) (1 trial)

glucarpidase (voraxaze) (1 trial)

idelalisib (zydelig) (1 trial)

imatinib (gleevec) (1 trial)

ipilimumab (yervoy) (1 trial)

lenvatinib (lenvima) (1 trial)

methotrexate (1 trial)

midostaurin (rydapt) (1 trial)

nivolumab (opdivo) (1 trial)

obinutuzumab (gazyva) (1 trial)

panobinostat (farydak) (1 trial)

pemigatinib (Pemazyre) (1 trial)

ponatinib (iclusig) (1 trial)

rituximab (rituxan) (1 trial)

ruxolitinib (jakafi) (2 trials)

sirolimus (rapamune) (1 trial)

sorafenib (nexavar) (1 trial)

sunitinib (sutent) (1 trial)

tafasitamab (Monjuvi) (1 trial)

tipiracil (lonsurf) (1 trial)

trametinib (mekinist) (1 trial)

tretinoin (Retin-A) (1 trial)

trifluridine (viroptic) (1 trial)

venetoclax (venclexta) (3 trials)

vorinostat (zolinza) (1 trial)

zn-c3 (1 trial)

Drugs in Other Trials (6)

68ga−psma−hbed−cc (1 trial)

calendula (1 trial)

fiber (1 trial)

lidocaine (xylocaine) (1 trial)

polyethylene glycol (1 trial)

silver sulfadiazine (silvadene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Cranial Nerve Diseases (Phase 2)

Glioblastoma (Phase 2)

Hypersensitivity (Phase 2)

Laboratory Infection (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Prolymphocytic (Phase 1)

Leukemia, Prolymphocytic, B-Cell (Phase 1)

Liposarcoma (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Nervous System Neoplasms (Phase 2)

Osteosarcoma (Phase 1)

Pancreatic Neoplasms (Phase 2)

Paresis (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Retroperitoneal Neoplasms (Phase 1)

Sarcoma (Phase 1)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Thrombosis (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Unconsciousness (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 106